Up-regulated expression of stathmin may be associated with hepatocarcinogenesis

Oncology Reports

Volumn 23, Issue 4, 2010, Pages 1037-1043

  Gan, Lin ^a   Guo, Kun ^a   Li, Yan ^a   Kang, Xiaonan ^a   Sun, Lu ^a   Shu, Hong ^a   Liu, Yinkun ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Carcinogenesis; Hepatocellular carcinoma; RNA interference; Stathmin

Indexed keywords

CHOLECYSTOKININ OCTAPEPTIDE; SMALL INTERFERING RNA; STATHMIN;

ARTICLE; CELL ADHESION; CELL COUNT; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; GENE SILENCING; GENETIC TRANSFECTION; HEPATITIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; METASTASIS POTENTIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; UPREGULATION;

APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL ADHESION; CELL MOVEMENT; CELL SEPARATION; CELL TRANSFORMATION, NEOPLASTIC; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; STATHMIN; TISSUE ARRAY ANALYSIS; TRANSFECTION; UP-REGULATION;

EID: 77949461914     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000730     Document Type: Article

References (29)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
2. El-Serag HB and Rudolph KL: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132: 2557-2576, 2007.
3. Colombo M: Hepatocellular carcinoma. J Hepatol 15: 225-236, 1992.
4. Sun M, Eshleman JR, Ferrell LD, Jacobs G, Sudilovsky EC, Tuthill R, Hussein MR and Sudilovsky O: An early lesion in hepatic carcinogenesis: loss of heterozygosity in human cirrhotic livers and dysplastic nodules at the 1p36-p34 region. Hepatology 33: 1415-1424, 2001.
5. Boige V, Laurent-Puig P, Fouchet P, Flejou JF, Monges G, Bedossa P, Bioulac-Sage P, Capron F, Schmitz A, Olschwang S and Thomas G: Concerted non-syntenic allelic losses in hyperploid hepatocellular carcinoma as determined by a highresolution allelotype. Cancer Res 57: 1986-1990, 1997.
6. Kusano N, Shiraishi K, Kubo K, Oga A, Okita K and Sasaki K: Genetic aberrations detected by comparative genomic hybridization in hepatocellular carcinomas: their relationship to clinico-pathological features. Hepatology 29: 1858-1862, 1999.
7. Piao Z, Kim H, Malkhosyan S and Park C: Frequent chromosomal instability but no microsatellite instability in hepatocellular carcinomas. Int J Oncol 17: 507-512, 2000.
8. Katoh H, Shibata T, Kokubu A, Ojima H, Loukopoulos P, Kanai Y, Kosuge T, Fukayama M, Kondo T, Sakamoto M, Hosoda F, Ohki M, Imoto I, Inazawa J and Hirohashi S: Genetic profile of hepatocellular carcinoma revealed by array-based comparative genomic hybridization: identification of genetic indicators to predict patient outcome. J Hepatol 43: 863-874, 2005.
9. Fang W, Piao Z, Simon D, Sheu JC and Huang S: Mapping of a minimal deleted region in human hepatocellular carcinoma to 1p36.13-p36.23 and mutational analysis of the riz (prdm2) gene localized to the region. Genes Chromosomes Cancer 28: 269-275, 2000.
10. Leung TH, Wong N, Lai PB, Chan A, To KF, Liew CT, Lau WY and Johnson PJ: Identification of four distinct regions of allelic imbalances on chromosome 1 by the combined comparative genomic hybridization and microsatellite analysis on hepatocellular carcinoma. Mod Pathol 15: 1213-1220, 2002.
11. Koshikawa K, Nomoto S, Yamashita K, Ishigure K, Takeda S and Nakao A: Allelic imbalance at 1p36 in the pathogenesis of human hepatocellular carcinoma. Hepatogastroenterology 51: 186-191, 2004.
12. Nishimura T, Nishida N, Itoh T, Komeda T, Fukuda Y, Ikai I, Yamaoka Y and Nakao K: Discrete breakpoint mapping and shortest region of overlap of chromosome arm 1q gain and 1p loss in human hepatocellular carcinoma detected by semiquantitative microsatellite analysis. Genes Chromosomes Cancer 42: 34-43, 2005.
13. Ozon S, Byk T and Sobel A: Sclip: a novel scg10-like protein of the stathmin family expressed in the nervous system. J Neurochem 70: 2386-2396, 1998.
14. Pellier-Monnin V, Astic L, Bichet S, Riederer BM and Grenningloh G: Expression of scg10 and stathmin proteins in the rat olfactory system during development and axonal regeneration. J Comp Neurol 433: 239-254, 2001.
15. Curmi PA, Nogues C, Lachkar S, Carelle N, Gonthier MP, Sobel A, Lidereau R and Bieche I: Overexpression of stathmin in breast carcinomas points out to highly proliferative tumours. Br J Cancer 82: 142-150, 2000.
16. Price DK, Ball JR, Bahrani-Mostafavi Z, Vachris JC, Kaufman JS, Naumann RW, Higgins RV and Hall JB: The phosphoprotein op18/stathmin is differentially expressed in ovarian cancer. Cancer Invest 18: 722-730, 2000.
17. Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, Xiao YS, Xu Y, Li YW and Tang ZY: Intratumoral balance of regulatory and cytotoxic t cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 25: 2586-2593, 2007.
18. Spessotto P, Giacomello E and Perri R: Improving fluorescencebased assays for the in vitro analysis of cell adhesion and migration. Mol Biotechnol 20: 285-304, 2002.
19. Bieche I, Maucuer A, Laurendeau I, Lachkar S, Spano AJ, Frankfurter A, Levy P, Manceau V, Sobel A, Vidaud M and Curmi PA: Expression of stathmin family genes in human tissues: non-neural-restricted expression for sclip. Genomics 81: 400-410, 2003.
20. Ghosh R, Gu G, Tillman E, Yuan J, Wang Y, Fazli L, Rennie PS and Kasper S: Increased expression and differential phosphorylation of stathmin may promote prostate cancer progression. Prostate 67: 1038-1052, 2007.
21. Belletti B, Nicoloso MS, Schiappacassi M, Berton S, Lovat F, Wolf K, Canzonieri V, D'Andrea S, Zucchetto A, Friedl P, Colombatti A and Baldassarre G: Stathmin activity influences sarcoma cell shape, motility and metastatic potential. Mol Biol Cell 19: 2003-2013, 2008.
22. Brattsand G: Correlation of oncoprotein 18/stathmin expression in human breast cancer with established prognostic factors. Br J Cancer 83: 311-318, 2000.
23. Xi W, Rui W, Fang L, Ke D, Ping G and Hui-Zhong Z: Expression of stathmin/op18 as a significant prognostic factor for cervical carcinoma patients. J Cancer Res Clin Oncol 135: 837-846, 2009.
24. Luo XN, Mookerjee B, Ferrari A, Mistry S and Atweh GF: Regulation of phosphoprotein p18 in leukemic cells. Cell cycle regulated phosphorylation by p34cdc2 kinase. J Biol Chem 269: 10312-10318, 1994.
25. Brattsand G, Marklund U, Nylander K, Roos G and Gullberg M: Cell-cycle-regulated phosphorylation of oncoprotein 18 on ser16, ser25 and ser38. Eur J Biochem 220: 359-368, 1994.
26. Borghese L, Fletcher G, Mathieu J, Atzberger A, Eades WC, Cagan RL and Rorth P: Systematic analysis of the transcriptional switch inducing migration of border cells. Dev Cell 10: 497-508, 2006.
27. Jin K, Mao XO, Cottrell B, Schilling B, Xie L, Row RH, Sun Y, Peel A, Childs J, Gendeh G, Gibson BW and Greenberg DA: Proteomic and immunochemical characterization of a role for stathmin in adult neurogenesis. FASEB J 18: 287-299, 2004.
28. Ozon S, Guichet A, Gavet O, Roth S and Sobel A: Drosophila stathmin: a microtubule-destabilizing factor involved in nervous system formation. Mol Biol Cell 13: 698-710, 2002.
29. Larsson N, Marklund U, Gradin HM, Brattsand G and Gullberg M: Control of microtubule dynamics by oncoprotein 18: dissection of the regulatory role of multisite phosphorylation during mitosis. Mol Cell Biol 17: 5530-5539, 1997.